The AI Impact with Generate:Biomedicines' Mike Nally

Business Of Biotech

We love to hear from our listeners. Send us a message.

Few drug discovery and development concepts are as hyped, and as such, draw as much polarity from drug developers, as machine learning and artifical intelligence. One company on the bullish end of the spectrum is Flagship Pioneering's Generate Biomedicines, which bills itself at the "intersection of machine learning, biological engineering, and medicine." To get a grip on the "generative biology" work it's doing and the AI/ML impact it anticipates in the discovery and development of therapeutics, as well as clinical trials, we sat down with veteran biotech builder Mike Nally, CEO at Generate and CEO-Partner at Flagship Pioneering.
Register for Bioprocess Online’s Bio Expo Live, being held July 30th through August 1st . This inaugural expo is a fantastic opportunity for biopharma companies and contract manufacturers to evaluate the latest and greatest from the comfort of your desktop or mobile device. Conveniently, we’ve broken down the lineup into Upstream Solutions July 30th, Downstream Solutions July 31st, and Quality, Analytical, and Data Solutions August 1st. It’s absolutely free to register for this series of short, digestible, and interactive sessions -- just hit the links above to register for Bio Expo Live today!

Chapters

1. The Business of Biotech (00:00:00)

2. Company Impact on Humanity and Biotech (00:10:34)

3. Series C Financing and Investor Relations (00:26:47)

4. Impact of Generative AI in Biology (00:33:30)

5. Innovating Drug Discovery Through Data (00:47:11)

6. Navigating Innovation in Biotech Ecosystem (01:04:31)

7. Biotech Podcast Subscription and Community (01:13:05)